Highdose Ara-C/Idarubicin induction and high dose Etoposide/Cytoxan intensification in AML.

被引：0
|
作者：
Kurian, S [1 ]
Qazilbash, MH [1 ]
Lynch, JP [1 ]
Beall, CL [1 ]
Weisenborn, R [1 ]
Bunner, P [1 ]
Hobbs, G [1 ]
Auber, M [1 ]
Ericson, SG [1 ]
机构：
[1] W Virginia Univ, Bone Marrow Transplant Program, Morgantown, WV USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4641
引用
收藏
页码：213B / 213B
页数：1
相关论文
共 50 条
  • [1] Idarubicin (IDA) and high dose cytosine arabinoside (HD ARA-C) for induction therapy for AML and AML arising from myelodysplasia (MDS/AML).
    Stein, AS
    ODonnell, MR
    Nademanee, A
    Parker, P
    Lee, J
    Molina, A
    Kashyap, A
    Spielberger, R
    Smith, E
    Planas, I
    Snyder, D
    Somlo, G
    Margolin, K
    Niland, J
    Forman, SJ
    BLOOD, 1995, 86 (10) : 2046 - 2046
  • [2] INTERMEDIATE-DOSE ARA-C AND IDARUBICIN FOLLOWED BY LOW-DOSE ARA-C IS PARTICULARLY EFFECTIVE IN UNMAINTAINED RELAPSED AML
    MUUS, P
    DEWITTE, T
    RAEMAEKERS, J
    BLOOD, 1994, 84 (10) : A146 - A146
  • [3] Idarubicin, high dose etoposide and high dose Ara-C (IDEA) treatment of high risk acute leukemia: A randomized study of schedule dependency of etoposide
    Johnston, L
    Damon, L
    Ries, C
    Rugo, H
    Linker, C
    BLOOD, 1996, 88 (10) : 855 - 855
  • [4] SEQUENTIAL HIGH-DOSE ARA-C AND ASPARAGINASE IN UNTREATED AML EFFICACY OF A SINGLE DAILY DOSE OF HIGH-DOSE ARA-C
    POWELL, BL
    CRUZ, JM
    LYERLY, ES
    RUSSELL, GB
    WOOD, JH
    STUART, RK
    CHORLEY, HM
    CAPIZZI, RL
    BLOOD, 1993, 82 (10) : A129 - A129
  • [5] Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
    Russo, D
    Malagola, M
    Vivo, A
    Fiacchini, M
    Martinelli, G
    Piccaluga, PP
    Damiani, D
    Candoni, A
    Michielutti, A
    Castelli, M
    Testoni, N
    Ottaviani, E
    Rondoni, M
    Pricolo, G
    Mazza, P
    Zuffa, E
    Zaccaria, A
    Raspadori, D
    Bocchia, M
    Lauria, F
    Bonini, A
    Avanzini, P
    Gugliotta, L
    Visani, G
    Fanin, R
    Baccarani, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) : 172 - 179
  • [6] High dose idarubicin (HIda) with high dose cytarabine (HiDac) as induction therapy for newly diagnosed patients with AML.
    Maslak, P
    Weiss, M
    Jurcic, J
    Jimenez, J
    Berman, E
    Golde, D
    Scheinberg, D
    BLOOD, 1998, 92 (10) : 231A - 231A
  • [7] Adaptively randomized prospective study of Troxacitabine and Ara-c (A), Troxacitabine and Idarubicin (I), and IA in older patients with unfavorable karyotype AML.
    Giles, F
    Estey, E
    Cortes, J
    Thomas, D
    Ferrajoli, A
    Faderl, S
    Verstovsek, S
    Wathen, K
    O'Brien, S
    Kantarjian, H
    BLOOD, 2002, 100 (11) : 563A - 564A
  • [8] IMPACT OF BUSULFAN, ETOPOSIDE AND HIGH-DOSE ARA-C (BEA) CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML
    Sanz, Jaime
    Labopin, Myriam
    Daskalakis, Michael
    Broers, A. E. C.
    Van Gorkom, Gwendolyn
    Meijer, Ellen
    Gedde-Dah, Tobias
    Montoro, Juan
    Arcese, William
    Antonio Perez-Simon, Jose
    Schaap, N.
    Maertens, Johan
    Vrhovac, Radovan
    Lanza, Francesco
    Gorin, Norbert Claude
    Mohty, Mohamad
    Ciceri, Fabio
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 57 - 57
  • [9] Rapamycin enhances ARA-C and idarubicin induced apoptosis in AML in vitro.
    Snell, V
    Consoli, U
    Hude, K
    Mills, G
    Andreeff, M
    BLOOD, 1995, 86 (10) : 2040 - 2040
  • [10] Personalization of Induction Therapy for Pediatric AML to Ara-C plus Dauno plus Etoposide (ADE) or Clofarabine plus Ara-C According to a Polygenic Ara-C SNP Score-ACS10
    Lamba, Jatinder K.
    Marrero, Richard J.
    Elsayed, Abdelrahman H.
    Cao, Xueyuan
    Wu, Huiyun
    Inaba, Hiroto
    Raimondi, Susana C.
    Pui, Ching-Hon
    Ribeiro, Raul C.
    Rubnitz, Jeffrey E.
    Pounds, Stanley B.
    BLOOD, 2022, 140 : 1039 - 1040
12345